Phase II study of PM60184 in patients with advanced colon-rectal cancer after standard treatment.
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Primary objectives: To evaluate the efficacy of PM060184 in terms ofprogression-free survival at 12 weeks (PFS3) in patients withadvanced colorectal carcinoma (CRC) after standard therapy. Primary endpoints: PFS3, defined as the percentage of patients remaining aliveand progression-free at Week 12 (Month 3) after the firsttreatment dose.
创建时间：
2017-12-15
